| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q1 2018 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Pardes Biosciences Inc | 4 | Q3 2022 | 57.4% |
| Theseus Pharmaceuticals, Inc. | 4 | Q3 2022 | 16.7% |
| Gemini Therapeutics, Inc. | 4 | Q3 2022 | 12.0% |
| Quantum-Si Incorporated | 4 | Q3 2022 | 10.5% |
| Kinnate Biopharma Inc. | 4 | Q3 2022 | 10.5% |
| Compass Therapeutics, Inc. | 4 | Q3 2022 | 10.6% |
| Adicet Bio, Inc. | 4 | Q3 2022 | 7.3% |
| Enanta Pharmaceuticals, Inc. | 3 | Q3 2022 | 3.5% |
| Cue Health Inc. | 2 | Q1 2022 | 13.7% |
| Cullinan Oncology, Inc. | 2 | Q1 2022 | 4.8% |
View Foresite Capital Opportunity Management V, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-05 |
| 4 | 2023-08-31 |
| 4 | 2023-07-19 |
| 4 | 2023-05-10 |
| 4 | 2023-04-06 |
| 4 | 2023-02-22 |
| 4 | 2023-01-03 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 3 | 2022-06-13 |
View Foresite Capital Opportunity Management V, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.